Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angelman Syndrome Therapy
Studies from University of Montreal further understanding of Angelman syndrome therapy
April 10th, 2007
Current study results from the report, "Lamotrigine therapy of epilepsy with Angelman's syndrome," have been published. "Angelman syndrome (AS) is a neurogenetic disorder characterized by developmental delay and a frequently refractory epileptic condition. Valproate, clonazepam and/or phenytoin are said to be the most effective antiepileptic drugs (AEDs) against the seizures in AS," scientists in Montreal, Canada report. "Experience with the newer AEDs is very limited despite their better safety profile and tolerability. Considering its favorable side effect profile and its effectiveness against both partial and generalized seizures, we hypothesized that lamotrigine...
Source: Drug Law Weekly (2007-04-10)
|
